BIOGNOSYS
15.3.2022 14:02:09 CET | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.
Proteome editing with TPD is a new frontier of medicine, aimed at expanding the druggable proteome. Biognosys’ TrueSignature™ platform uniquely offers high-precision proteomic panels that provide actionable insights based on highly specific and sensitive, absolute quantification of pharmacodynamic and efficacy biomarkers. These custom panels allow Kymera to monitor and quantify protein degradation. The ease of transferability of the assays — from early discovery, across preclinical evaluation, to clinical development — enables integration into all stages of Kymera’s drug development process . The panels are developed and performed at Biognosys’ state-of-the-art facility, the largest high-end, GLP certified and GCP compliant mass spectrometry laboratory worldwide for large-scale proteomics contract research.
“Kymera’s novel approach to targeted protein degradation is a great example of the power of proteomics-enabled drug development,” said Kristina Beeler, Ph.D., Chief Business Officer of Biognosys . “We are glad to see the impact our TrueSignature platform is having, not only on the advancement of Kymera’s clinical trial programs, but also on patients’ lives.”
The current partnership between Kymera and Biognosys builds upon the longstanding scientific relationship between the two companies across early R&D, preclinical, and clinical settings across oncology and inflammation.
“Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications,” said Nello Mainolfi, Ph.D., Co-Founder, President and CEO, Kymera Therapeutics . “The company’s high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs.”
About TrueSignature™
The Biognosys TrueSignature™ platform provides high-precision customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring.
Parallel Reaction Monitoring mass-spectrometry powers the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature™ panels offer an unprecedented level of multiplexing, enabling the simultaneous absolute quantification of up to 100 proteins.
TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies guide the choice of proteins in the custom panel. The measurements are performed with unprecedented speed and throughput at Biognosys' state-of-the-art facility, the world's largest high-end GLP-certified and GCP-compliant mass spectrometry laboratory. For more information, visit truesignature.bio
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers, and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Launches Cash Tender Offer11.3.2026 13:25:00 CET | Press release
THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE MARKET ABUSE REGULATION (EU) 596/2014. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT)) OR IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (SEE “OFFER AND DISTRIBUTION RESTRICTIONS” BELOW). SES (the “Offeror”) announces today that it is inviting holders of its outstanding €625,000,000 Deeply Subordinated Fixed Rate Re
Thredd and Cross River to Accelerate Expansion into the US Market for Global Fintechs11.3.2026 13:01:00 CET | Press release
B4B Payments scales U.S. operations through collaboration Thredd, the AI-first issuer processing platform, today announced a strategic alliance with Cross River Bank (“Cross River”), a technology infrastructure provider that offers embedded financial solutions. The relationship is designed to accelerate the entry of international fintechs into the United States. This collaboration leverages Thredd’s global expertise and technology stack with Cross River’s proprietary core infrastructure, established market leadership and regulatory expertise, creating a seamless pathway for innovative payment solutions to launch and scale in the U.S. As part of this agreement, Thredd becomes one of Cross River’s select strategic processing partners outside of the bank’s own stack. The arrangement enables Thredd to introduce a curated pipeline of high-potential fintech clients from various geographic regions*.1 In turn, Thredd’s clients benefit from Cross River’s proven ability to deliver compliant, sca
SLB Provides Update on Middle East Operations and First Quarter Outlook11.3.2026 13:00:00 CET | Press release
SLB (NYSE: SLB) continues to closely monitor the unfolding situation in the Middle East and adapt its operations. The safety and security of SLB’s employees is the highest priority, and the company has activated local and regional crisis response teams that are meeting daily. Travel to and transit through the region have been suspended, and the company has begun to demobilize operations in a few countries in response to customer actions to safeguard personnel and facilities. These measures will continue as long as necessary until the environment in the region has stabilized. SLB is working closely with local authorities and its customers to monitor the situation and will begin a phased resumption of full activity as conditions allow. SLB revenue for the first quarter will be lower than expected, and the company expects to incur additional costs resulting in an impact of approximately 6-9 cents of earnings per diluted share for the first quarter. Given the dynamic nature of the environm
IQM Delivers Fourth Quantum Computer in Finland, Operational at Aalto University11.3.2026 11:32:00 CET | Press release
This is the fourth quantum computer deployed by IQM to customers in Finland to boost research and education in a growing ecosystem. The system named Aalto Q20 quantum computer is online at Aalto University and will enable students and scientists a unique first-hand access to a world-class quantum computer. The university will use the quantum computer to perform scientific experiments on advanced level and to support national and European quantum research activities. IQM Quantum Computers, the global leader in deployed on-premises, full-stack superconducting quantum computers, today announced the launch of Aalto Q20 quantum computer in Finland, reinforcing its commercial leadership in the quantum industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311215316/en/ Ribbon cutting of the Aalto Q20 quantum computer delivered by IQM. The 20-qubit system, which is operational at Aalto University, is the fourth quantum compute
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 11:00:00 CET | Press release
Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissionsBespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resiliencePartnership aligns with the science-based climate commitments of both companies Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom